Jefferies reiterated a Buy rating and $8.00 price target on Aratana Therapeutics (NASDAQ: PETX) following the company's Galliprant launch. Analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE